Rabo to price 8.6% knock-in reverse convertibles linked to Pfizer via LaSalle

By Jennifer Chiou

New York, April 3 - Rabo Financial Products BV plans to price 8.6% knock-in reverse convertible notes due April 25, 2008 linked to Pfizer Inc. common stock.

Interest will be payable monthly.

In addition to the coupon, at maturity investors will receive par unless Pfizer stock falls below the knock-in price - 85% of the initial share price - during the life of the notes and finishes below the initial share price, in which case the payout will be a number of Pfizer shares equal to $1,000 divided by the initial share price.

The notes will price on April 20 and settle on April 25.

LaSalle Financial Services, Inc. is the agent.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.